Long-Term Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: An Open-Label 12-Month Extension to the CANTREAT Study

Long-Term Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: An Open-Label 12-Month Extension to the CANTREAT Study

INTRODUCTION: The objective of this study is to assess the long-term effectiveness of a treat-and-extend (T&E) anti-vascular endothelial growth factor regimen in patients with neovascular age-related macular degeneration who remain on T&E and those switched from once-monthly (OM) dosing to T...

Full description

Bibliographic Details
Main Authors: Baker, J. (Author), CANTREAT Investigators (Author), Galic, I.J (Author), Greve, M. (Author), Kertes, P.J (Author), Sheidow, T. (Author), Williams, G. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
angiogenesis inhibitor
Angiogenesis Inhibitors
Best-corrected visual acuity
human
Humans
Injections
intravitreal drug administration
Intravitreal Injections
macular degeneration
Macular Degeneration
Neovascular age-related macular degeneration
optical coherence tomography
ranibizumab
Ranibizumab
Tomography, Optical Coherence
Treat and extend
treatment outcome
Treatment Outcome
Vascular Endothelial Growth Factor A
vasculotropin A
visual acuity
Visual Acuity
wet macular degeneration
Wet Macular Degeneration
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items